Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Congress Wants Answers From US FDA On China And India Inspection Plans

Aug 17 2023

• By Michael McCaughan

drug manufacturing — • Source: Shutterstock

Related Content

US FDA’s Biggest Post-COVID Challenge May Be Helped By Small Inspections Tweak In FDORA

Feb 01 2023

House Republicans: Drug Shortage Solutions Must Move Beyond FDA

Jul 14 2023

US FDA Finds Poor Data Integrity At Second Intas Plant

Jul 17 2023

Litigation Follows OTC Eye Drops Recall Due To Bacteria Strain Not Previously Seen In US

Feb 21 2023

Related Companies

Intas Pharmaceuticals Ltd.

Qilu Pharmaceutical Co., Ltd.

Additional Topics

Asia Pacific United States International China India OTC Drugs Politics Regulation Manufacturing Quality FDA Ingredients Legislation Consumer Compliance Safety BioPharmaceutical

More from Regulation

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window